Study of ALK-001 on the Progression of Stargardt Disease

Официальное название

A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK 001) on the Progression of Stargardt Disease (STGD)

Обзор

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

Вмешательства

• Препарат ALK-001
  Daily oral administration for 24 months
• Препарат Placebo
  Daily oral administration for 24 months

Первичные конечные точки

• Annualized growth rate of retinal atrophic lesions measured by Fundus Autofluorescence [Срок оценки: Month 6 to Month 24]

Вторичные конечные точки (1)

• Changes in Low Luminance Visual Acuity from baseline to Month 24 [Срок оценки: baseline to Month 24]

Критерии участия

Критерии включения

• Male or female, 8 to 45 years of age (inclusive) on the day of screening.
• Female participants of childbearing potential, as well as fertile male participants with female partners of childbearing potential, must be willing to comply with the protocol-defined methods of contraception from the time of consent until 90 days and 30 days, respectively, after the last dose of IMP.
• Have a clinical diagnosis of typical autosomal recessive STGD macular dystrophy
• Have provided a genetic report by any regional accredited organization that provides certified testing indicating the presence of disease-causing mutation.
• Have signed and dated the informed consent forms (ICFs; or assent as appropriate) to participate.

Критерии исключения

• Has taken disallowed items (supplements containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) within 30 days of randomization.
• Is lactating, pregnant, or has a positive serum or urine pregnancy test at screening or at randomization, or is planning to become pregnant during the course of study. A male participant who wishes to father a child during the course of the study.
• Has ever participated in any gene therapy, cell therapy, or device study to treat STGD, unless documented confirmation of participation in the placebo arm with no surgery is provided. Has participated in a drug study to treat STGD within the past 6 months.
• Has participated in any drug study to treat any other condition within 5 half-lives of the investigational drug prior to screening, unless documented confirmation of participation in the placebo arm is provided. Has participated in an investigational device study within 30 days prior to screening or longer if, in the Investigator's judgment, the device could affect study outcomes.
• Anticipates participating in any other drug or device study within the duration of the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

США · 5 центров

• Associated Retina Consultants — Phoenix
• Vitreo Retinal Associates — Gainesville
• Erie Retina Research — Erie
• Retina Foundation of the Southwest — Dallas
• Star Retina — Fort Worth

Идентификаторы

NCT: NCT07419334 · ALK001-P1004 · 2026-525296-60-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗